<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04499989</url>
  </required_header>
  <id_info>
    <org_study_id>aswu/353/4/19</org_study_id>
    <nct_id>NCT04499989</nct_id>
  </id_info>
  <brief_title>Vaginal Isonicotinic Acid Hydrazide (INH) Administration Prior to T380A Intrauterine Device Insertion</brief_title>
  <official_title>Clinical Outcomes of Vaginal Isonicotinic Acid Hydrazide (INH) Administration Prior to T380A Intrauterine Device Insertion in Women Delivered Only by Cesarean Delivery: a Randomized Double Blinded Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aswan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aswan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate whether vaginal isonicotinic acid hydrazide administered before intrauterine&#xD;
      device (IUD) insertion reduces failed insertions, insertion-related complications and pain in&#xD;
      in Women Delivered Only by Cesarean Delivery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women may experience pain and technical difficulties may be encountered when insertion of an&#xD;
      intrauterine device is attempted through a narrow cervical canal. intrauterine device&#xD;
      insertion- related complications and side effects are more common among women who had never&#xD;
      delivered vaginally.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Actual">August 1, 2021</completion_date>
  <primary_completion_date type="Actual">June 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>double blind randomized trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>double blind randomized trial</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>the difference in the pain intensity scores between the study groups</measure>
    <time_frame>10 minutes</time_frame>
    <description>the difference in the pain intensity scores between the study groups at IUD insertion BY10 cm visual analog scale score where 0 denotes no pain and 10 denotes the most imaginable pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Provider ease of insertion</measure>
    <time_frame>10 minutes</time_frame>
    <description>Provider ease of insertion was evaluated using a visual analog scale from 0 to 10 cm where 0 denotes very easy insertion and 10 denotes a very difficult insertion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>insertion time</measure>
    <time_frame>10 minutes</time_frame>
    <description>IUD insertion time from speculum in to speculum out</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>IUCD Complication</condition>
  <arm_group>
    <arm_group_label>INH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 vaginal tablet of isonicotinic acid hydrazide self-inserted by the patient 12 hours before IUD insertion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 vaginal tablet of Placebo Comparator self-inserted by the patient 12 hours before IUD insertion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INH</intervention_name>
    <description>3 vaginal tablet of isonicotinic acid hydrazide self inserted 12 hours before IUD insertion.</description>
    <arm_group_label>INH</arm_group_label>
    <other_name>isonicotinic acid hydrazide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator</intervention_name>
    <description>3 vaginal tablet of Placebo Comparator self inserted 12 hours before IUD insertion</description>
    <arm_group_label>Placebo Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Non-pregnant women&#xD;
&#xD;
          -  Women that did not receive any analgesics or Dinoprostone in the 24 hours prior to&#xD;
             insertion&#xD;
&#xD;
          -  Women who delivered only by cesarean section&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women with any uterine abnormalities as congenital anomalies, endometrial lesions,&#xD;
             adenomyosis, fibroids.&#xD;
&#xD;
          -  Those with a Category 3 or 4 conditions for intrauterine device insertion according to&#xD;
             the WHO Medical Eligibility Criteria for contraceptive use&#xD;
&#xD;
          -  Allergy to isonicotinic acid hydrazide .&#xD;
&#xD;
          -  Women refuse to participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Women Delivered Only by Elective Cesarean Section</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>nahla w Shady, md</last_name>
    <role>Study Chair</role>
    <affiliation>Aswan universirty</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aswan University Hospital</name>
      <address>
        <city>Aswan</city>
        <zip>81528</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 2, 2020</study_first_submitted>
  <study_first_submitted_qc>August 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2020</study_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aswan University Hospital</investigator_affiliation>
    <investigator_full_name>hany farouk</investigator_full_name>
    <investigator_title>A Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isoniazid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

